- Home
- LDI vs IMNM Comparison
LDI vs IMNM Comparison
Compare LDI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- IMNM
- Stock Information
- Founded
- LDI 2010
- IMNM 2006
- Country
- LDI United States
- IMNM United States
- Employees
- LDI N/A
- IMNM N/A
- Industry
- LDI Finance: Consumer Services
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- LDI Finance
- IMNM Health Care
- Exchange
- LDI Nasdaq
- IMNM Nasdaq
- Market Cap
- LDI 894.0M
- IMNM 945.8M
- IPO Year
- LDI 2021
- IMNM 2020
- Fundamental
- Price
- LDI $4.28
- IMNM $9.21
- Analyst Decision
- LDI Sell
- IMNM Strong Buy
- Analyst Count
- LDI 3
- IMNM 8
- Target Price
- LDI $2.30
- IMNM $24.75
- AVG Volume (30 Days)
- LDI 10.8M
- IMNM 1.0M
- Earning Date
- LDI 11-04-2025
- IMNM 11-12-2025
- Dividend Yield
- LDI N/A
- IMNM N/A
- EPS Growth
- LDI N/A
- IMNM N/A
- EPS
- LDI N/A
- IMNM N/A
- Revenue
- LDI $1,124,074,000.00
- IMNM $12,589,000.00
- Revenue This Year
- LDI $21.95
- IMNM N/A
- Revenue Next Year
- LDI $15.72
- IMNM $154.73
- P/E Ratio
- LDI N/A
- IMNM N/A
- Revenue Growth
- LDI 27.06
- IMNM 16.74
- 52 Week Low
- LDI $1.01
- IMNM $5.15
- 52 Week High
- LDI $4.51
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- LDI 78.59
- IMNM 44.56
- Support Level
- LDI $3.01
- IMNM $8.67
- Resistance Level
- LDI $4.03
- IMNM $10.65
- Average True Range (ATR)
- LDI 0.36
- IMNM 0.70
- MACD
- LDI 0.22
- IMNM -0.07
- Stochastic Oscillator
- LDI 90.82
- IMNM 27.46
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.